Scarica l'app Stockscreener
33.70
3.34%
-0.875
Precedente Chiudi:
$34.57
Aprire:
$34.13
Volume 24 ore:
39,671
Relative Volume:
0.14
Capitalizzazione di mercato:
$1.51B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-12.06%
1M Prestazione:
-5.20%
6M Prestazione:
+39.23%
1 anno Prestazione:
+102.76%
Intervallo 1D:
$32.72
$34.67
Intervallo di 1 settimana:
$32.56
$38.32
Portata 52W:
$7.255
$45.00
Sionna Therapeutics Inc Stock (SION) Company Profile
Nome
Sionna Therapeutics Inc
Settore
Industria
Telefono
617-819-2020
Indirizzo
21 HICKORY DRIVE, SUITE 500, WALTHAM
Compare SION vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
33.84 | 1.54B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.18 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.05 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
731.68 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.49 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
295.38 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-01 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2025-11-19 | Iniziato | BTIG Research | Buy |
| 2025-09-03 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-03-04 | Iniziato | Guggenheim | Buy |
| 2025-03-04 | Iniziato | Stifel | Buy |
| 2025-03-04 | Iniziato | TD Cowen | Buy |
Mostra tutto
Sionna Therapeutics Inc Borsa (SION) Ultime notizie
TD Asset Management Inc Grows Position in Sionna Therapeutics, Inc. $SION - MarketBeat
Reassessing Sionna Therapeutics (SION) Valuation After Recent Share Price Pullback And CF Pipeline Progress - simplywall.st
UBS Maintains Buy on Sionna Therapeutics, Inc. (SION) March 02, 2026 - Meyka
SION: NBD1 stabilization could transform CF care, with dual and add-on therapies advancing in clinical trials - TradingView
Sionna Therapeutics (NASDAQ:SION) Earns Buy Rating from BTIG Research - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Shares Gap DownShould You Sell? - MarketBeat
Sionna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Guggenheim raises Sionna Therapeutics stock price target to $50 By Investing.com - Investing.com Canada
Sionna Therapeutics Inc maintains strong cash position with about $310.3 million in cash and cash equivalents, expected to fund operations into 2028 - marketscreener.com
Sionna Therapeutics Inc Maintains Strong Cash Position With About $310.3 Million In Cash And Cash Equivalents, Expected To Fund Operations Into 2028 - TradingView
Form S-3ASR Sionna Therapeutics, - StreetInsider
Sionna Therapeutics Q4 Net Loss Narrows - marketscreener.com
Sionna Therapeutics (SION) outlines NBD1-focused cystic fibrosis drug pipeline - Stock Titan
Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Sionna Therapeutics 10-K: $0 Revenue, $(1.88) EPS - TradingView
Sionna Therapeutics (Nasdaq: SION) posts 2025 loss, ends year with $310.3M cash - Stock Titan
Sionna backs cystic fibrosis trials with $310M cash runway to 2028 - Stock Titan
Assessing Sionna Therapeutics (SION) Valuation As Premium P/B Meets Cooling Share Price Momentum - Yahoo Finance
Sionna Therapeutics, Inc. (SION) Stock Analysis: A Promising 24% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Sionna Therapeutics (NASDAQ:SION) Rating Increased to Strong-Buy at Lifesci Capital - MarketBeat
JPMorgan Chase & Co. Cuts Stake in Sionna Therapeutics, Inc. $SION - MarketBeat
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Citizens Initiates Coverage of Sionna Therapeutics (SION) with Market Outperform Recommendation - Nasdaq
Sionna Therapeutics (NASDAQ:SION) Coverage Initiated by Analysts at Citizens Jmp - MarketBeat
Market Recap: Is FIVE in a consolidation phase2025 EndofYear Setup & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Cystic fibrosis drug developer Sionna heads to key March investor events - Stock Titan
Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences - The Manila Times
Sionna Therapeutics, Inc. (SION) Stock Analysis: A High-Stakes Bet on Biotech Innovation with 20.13% Upside Potential - DirectorsTalk Interviews
Is Sionna Therapeutics Inc. still a buy after recent gainsJuly 2025 Trade Ideas & Stepwise Trade Execution Plans - mfd.ru
Fed Meeting: Will Sionna Therapeutics Inc outperform tech stocks2025 AllTime Highs & Community Trade Idea Sharing Platform - baoquankhu1.vn
Sionna Therapeutics Maps Mid-2026 CF Catalysts, Highlights NBD1 Stabilizers at Guggenheim Summit - Yahoo Finance
2026 Milestones in Focus as Sionna Therapeutics Pursues NBD1 Stabilization for CFTR - AD HOC NEWS
Sionna Therapeutics, Inc. (SION) Investor Outlook: Analyzing a 19% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
SION: NBD1 stabilizer programs target major CF mutations, with pivotal data expected mid-2026 - TradingView
Can Sionna Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 Breakouts & Technical Confirmation Alerts - mfd.ru
What’s the MACD signal for Sionna Therapeutics Inc.July 2025 Outlook & Risk Adjusted Buy/Sell Alerts - mfd.ru
Volume Recap: Should you avoid Sionna Therapeutics Inc stock right nowEarnings Miss & Growth-Oriented Investment Plans - baoquankhu1.vn
Orbimed Advisors Llc Sells 29,063 Shares of Sionna Therapeutics (NASDAQ:SION) Stock - Defense World
Peter Thompson Sells 29,063 Shares of Sionna Therapeutics (NASDAQ:SION) Stock - Defense World
Sionna Therapeutics (NASDAQ:SION) Shares Down 14.6% on Insider Selling - Defense World
Sionna Therapeutics (NASDAQ:SION) Trading Down 14.6% Following Insider Selling - MarketBeat
OrbiMed Advisors LLC sells Sionna Therapeutics (SION) stock worth $1.37m - Investing.com Australia
OrbiMed Advisors LLC sells Sionna Therapeutics (SION) stock worth $1.37m By Investing.com - Investing.com South Africa
Thompson Peter a. sells Sionna Therapeutics (SION) shares for $1.37m By Investing.com - Investing.com South Africa
Thompson Peter a. sells Sionna Therapeutics (SION) shares for $1.37m - Investing.com Canada
Sionna Therapeutics (NASDAQ:SION) Director Orbimed Advisors Llc Sells 29,063 Shares - MarketBeat
Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - markets.businessinsider.com
Sionna Therapeutics (NASDAQ:SION) Director Sells $1,295,628.54 in Stock - MarketBeat
Support Test: Whats the outlook for Sionna Therapeutics Incs sectorTrade Risk Summary & Smart Allocation Stock Reports - baoquankhu1.vn
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
TPG GP A, LLC Reduces Stake in Sionna Therapeutics Inc - GuruFocus
Sionna Therapeutics Inc Azioni (SION) Dati Finanziari
Non sono disponibili dati finanziari per Sionna Therapeutics Inc (SION). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Sionna Therapeutics Inc Azioni (SION) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Thompson Peter A. | Director |
Feb 02 '26 |
Sale |
44.57 |
1,890 |
84,237 |
3,559,765 |
| ORBIMED ADVISORS LLC | Director |
Feb 03 '26 |
Sale |
44.58 |
29,063 |
1,295,629 |
3,530,702 |
| ORBIMED ADVISORS LLC | Director |
Feb 02 '26 |
Sale |
44.57 |
1,890 |
84,237 |
3,559,765 |
| TPG GP A, LLC | 10% Owner |
Jan 22 '26 |
Sale |
40.00 |
250,000 |
10,000,000 |
6,494,962 |
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):